ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO885

Effects of Dapagliflozin in Patients Without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials


  • L Heerspink, Hiddo Jan, Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Chertow, Glenn, Stanford University School of Medicine, Stanford, California, United States
  • Jongs, Niels, Universitair Medisch Centrum Groningen, Groningen, Groningen, Netherlands
  • Correa-Rotter, Ricardo, The National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Denmark
  • Sjostrom, David, AstraZeneca, Gothenburg, Sweden
  • Langkilde, Anna Maria, AstraZeneca, Gothenburg, Sweden
  • Wheeler, David C., University College London, London, London, United Kingdom

Group or Team Name

  • DAPA-CKD Trial Committee and Investigators

The DAPA-CKD trial demonstrated that the sodium glucose co-transporter 2 inhibitor dapagliflozin slows progressive kidney function loss in patients with CKD without type 2 diabetes. The majority of these participants had macroalbuminuria. Whether this effect persists in participants without type 2 diabetes and with microalbuminuria is unknown. We therefore assessed the effects of dapagliflozin on the rate of kidney function decline, albuminuria, and blood pressure in this subgroup.


DAPA-CKD randomized participants with or with type 2 diabetes and an urinary albumin-to-creatinine ratio (UACR) 200–5000 mg/g and eGFR 25–75 mL/min/1.73m2 to dapagliflozin 10 mg or placebo once daily, added to standard care. The kidney endpoint was a composite of sustained ≥50% eGFR decline, end-stage kidney disease or renal death. We analyzed, in participants without type 2 diabetes and with microalbuminuria (UACR<300 mg/g), eGFR slope using mixed effect models with slopes from baseline to Week 2 (acute change) and Week 2 to end-of-treatment (chronic eGFR slope). UACR change was an additional pre-specified exploratory outcome.


Of 4304 randomized participants, 136 (72 randomized to dapagliflozin and 64 to placebo) did not have type 2 diabetes and had a UACR <300 mg/g. Their mean age was 61 years, 49 (36%) were female, mean eGFR was 42 mL/min/1.73m2 and median UACR was 245 mg/g. In the dapagliflozin group UACR changed from baseline by -24.2% (95%CI -41.2, -2.3) versus -9.8% (-30.8, 17.7) in the placebo group (between group difference -16.0% [95%CI, -41.8, 21.3]). Compared to placebo, dapagliflozin caused an acute eGFR reduction of 2.4 mL/min/1.73m2 (95%CI 0.4, 4.5). Thereafter, dapagliflozin reduced the mean rate of eGFR decline by 1.8 mL/min/1.73m2 (95%CI 0.4, 3.1) compared to placebo. Few kidney endpoints occurred during follow-up (1 in the dapagliflozin group and 3 in the placebo group).


In patients without type 2 diabetes and with microalbuminuria, dapagliflozin slowed eGFR decline during chronic treatment suggesting that its kidney protective effects may extend to this subgroup of patients.


  • NIDDK Support –